Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic Cancer.

Autor: Cass SH; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Tzeng CD; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Prakash LR; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Maxwell J; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Snyder RA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Kim MP; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Huey RW; Department of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Smaglo BG; Department of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Pant S; Department of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Koay EJ; Department of GI Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Wolff RA; Department of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Lee JE; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Katz MHG; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Ikoma N; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

Publikováno v: Annals of surgery [Ann Surg] 2024 Mar 20. Date of Electronic Publication: 2024 Mar 20.

Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia.

Autor: Cass SH; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA., Tobin JWD; Haematology Department, Princess Alexandra Hospital, Woolloongabba; University of Queensland, Brisbane, Australia., Seo YD; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA., Gener-Ricos G; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston., Keung EZ; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA., Burton EM; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston., Davies MA; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston., McQuade JL; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston., Lazar AJ; Departments of Pathology and Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, USA., Mason R; Gold Coast University Hospital, Southport., Millward M; University of Western Australia, Perth., Sandhu S; Peter Macallum Cancer Centre, Melbourne., Khoo C; Peter Macallum Cancer Centre, Melbourne., Warburton L; Fiona Stanley Hospital, Perth; Edith Cowan University, Joondalup; Future Health Research and Innovation Fund/Raine Clinician Research Fellowship., Guerra V; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston., Haydon A; Alfred Hospital, Melbourne., Dearden H; Melanoma Institute Australia, The University of Sydney, Sydney., Menzies AM; Melanoma Institute Australia, The University of Sydney, Sydney; Faculty of Medicine and Health, The University of Sydney, Sydney; The University of Sydney Charles Perkins Centre, Sydney; The University of Sydney Royal North Shore and Mater Hospitals, Sydney., Carlino MS; Melanoma Institute Australia, The University of Sydney, Sydney; Westmead Hospital, Sydney, Australia., Smith JL; Westmead Hospital, Sydney, Australia., Mollee P; Haematology Department, Princess Alexandra Hospital, Woolloongabba; University of Queensland, Brisbane, Australia., Burgess M; Haematology Department, Princess Alexandra Hospital, Woolloongabba; University of Queensland, Brisbane, Australia., Mapp S; Haematology Department, Princess Alexandra Hospital, Woolloongabba; University of Queensland, Brisbane, Australia., Keane C; Haematology Department, Princess Alexandra Hospital, Woolloongabba; University of Queensland, Brisbane, Australia., Atkinson V; Haematology Department, Princess Alexandra Hospital, Woolloongabba; University of Queensland, Brisbane, Australia., Parikh SA; Mayo Clinic, Rochester, USA., Markovic SN; Mayo Clinic, Rochester, USA., Ding W; Mayo Clinic, Rochester, USA., Call TG; Mayo Clinic, Rochester, USA., Hampel PJ; Mayo Clinic, Rochester, USA., Long GV; Melanoma Institute Australia, The University of Sydney, Sydney; Faculty of Medicine and Health, The University of Sydney, Sydney; The University of Sydney Charles Perkins Centre, Sydney; The University of Sydney Royal North Shore and Mater Hospitals, Sydney., Wargo JA; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: jwargo@mdanderson.org., Ferrajoli A; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2023 Sep; Vol. 34 (9), pp. 796-805. Date of Electronic Publication: 2023 Jul 04.

Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration.

Autor: Zhou Y; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX., Medik YB; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX., Patel B; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX., Zamler DB; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.; The University of Texas MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX., Chen S; Ministry of Education Key Lab of Bioinformatics and Bioinformatics Division, Beijing National Research Center for Information Science and Technology; Department of Automation, Tsinghua University, Beijing, China., Chapman T; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Schneider S; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX.; The University of Texas MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX.; Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX., Park EM; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Babcock RL; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX.; The University of Texas MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX., Chrisikos TT; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX.; The University of Texas MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX., Kahn LM; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX.; The University of Texas MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX., Dyevoich AM; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX., Pineda JE; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX.; The University of Texas MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX., Wong MC; Platform for Innovative Microbiome and Translational Research, MD Anderson Cancer Center, Houston, TX., Mishra AK; Platform for Innovative Microbiome and Translational Research, MD Anderson Cancer Center, Houston, TX., Cass SH; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Cogdill AP; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.; The University of Texas MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX., Johnson DH; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Johnson SB; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Wani K; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Ledesma DA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Hudgens CW; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Wang J; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Wadud Khan MA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Peterson CB; The University of Texas MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX.; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX., Joon AY; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX., Peng W; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Li HS; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX., Arora R; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Tang X; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Raso MG; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Zhang X; Ministry of Education Key Lab of Bioinformatics and Bioinformatics Division, Beijing National Research Center for Information Science and Technology; Department of Automation, Tsinghua University, Beijing, China., Foo WC; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Tetzlaff MT; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Diehl GE; Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY., Clise-Dwyer K; Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX., Whitley EM; Department of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX., Gubin MM; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX.; The University of Texas MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX.; Parker Institute for Cancer Immunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX., Allison JP; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX.; The University of Texas MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX.; Parker Institute for Cancer Immunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX., Hwu P; The University of Texas MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX.; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Ajami NJ; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.; Platform for Innovative Microbiome and Translational Research, MD Anderson Cancer Center, Houston, TX., Diab A; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Wargo JA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.; The University of Texas MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX.; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.; Platform for Innovative Microbiome and Translational Research, MD Anderson Cancer Center, Houston, TX.; Parker Institute for Cancer Immunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX., Watowich SS; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX.; The University of Texas MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX.; Platform for Innovative Microbiome and Translational Research, MD Anderson Cancer Center, Houston, TX.

Publikováno v: The Journal of experimental medicine [J Exp Med] 2023 Feb 06; Vol. 220 (2). Date of Electronic Publication: 2022 Nov 11.

Bouveret syndrome: approaching the obstructive duodenal gallstone.

Autor: Coleoglou Centeno AA; Department of Surgery, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA., Shah NR; Department of Surgery, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA., Cass SH; Department of Surgery, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA., Walker JP; Department of Surgery, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA.

Publikováno v: Trauma surgery & acute care open [Trauma Surg Acute Care Open] 2022 May 26; Vol. 7 (1), pp. e000945. Date of Electronic Publication: 2022 May 26 (Print Publication: 2022).

The Microbiome: the Link to Colorectal Cancer and Research Opportunities.

Autor: Cass SH; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Unit 1484 PO Box 301402, Houston, TX, 77230, USA., Ajami NJ; Program for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., White MG; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Unit 1484 PO Box 301402, Houston, TX, 77230, USA. mgwhite@mdanderson.org.; Department of Colon and Rectal Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mgwhite@mdanderson.org.

Publikováno v: Current treatment options in oncology [Curr Treat Options Oncol] 2022 May; Vol. 23 (5), pp. 631-644. Date of Electronic Publication: 2022 Mar 07.